Avanos Medical (AVNS) 10-Q2024 Q3 Quarterly report

Filed: 30 Oct 24, 4:17pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: America, announced, attract, award, behavior, China, Committee, complexity, congressional, Corrupt, difficult, diminished, documentation, earned, exit, expansion, exploring, export, expropriation, flexibility, foregoing, fraudulent, full, high, impede, inadvertently, incentive, inherent, inherently, internationally, judicial, Kingdom, LRD, mitigate, negligent, North, payout, percentage, political, presidential, privacy, reputation, retain, robust, safety, salary, sanction, solution, source, staffing, sum, taxation, Trident, unchanged, violated

Removed: necessarily

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated AVNS transcripts

AVNS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32(b)

Certification of Chief Financial Officer

Pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code

I, Warren J. Machan, Interim Chief Financial Officer of Avanos Medical, Inc., certify that, to my knowledge:

(1)the Form 10-Q, filed with the Securities and Exchange Commission on October 30, 2024 (“accompanied report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)the information contained in the accompanied report fairly presents, in all material respects, the financial condition and results of operations of Avanos Medical, Inc.


Date: October 30, 2024						/s/ Warren J. Machan
						Warren J. Machan Interim Chief Financial Officer (Principal Financial Officer)